Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
NCT03748446Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2019
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xenon in major depressive disorder (MDD) and bipolar disorder (BD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Improvement in Depressive Symptoms at 1 day. Started Dec 2019; status: completed.
02
Drugs
xenon
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03748446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748446.